ZyVersa Therapeutics has filed a prospectus to register up to 1,637,000 shares of common stock for resale by warrant holders. The shares are issuable upon exercise of Series A-2 warrants issued in a private placement on November 6, 2024 at $2.06 per share.If all warrants are exercised for cash, ZyVersa could receive approximately $3.37 million in gross proceeds. The company intends to use any proceeds for working capital and general corporate purposes. ZyVersa will not receive proceeds from the actual resale of shares by the selling stockholders.The prospectus notes that ZyVersa's independent auditors have expressed substantial doubt about the company's ability to continue as a going concern, citing the need for additional funding to execute its business plans. ZyVersa is a clinical-stage biopharmaceutical company developing treatments for renal and inflammatory diseases.

ZyVersa Therapeutics has filed a prospectus to register up to 1,637,000 shares of common stock for resale by warrant holders. The shares are issuable upon exercise of Series A-2 warrants issued in a private placement on November 6, 2024 at $2.06 per share.If all warrants are exercised for cash, ZyVersa could receive approximately $3.37 million in gross proceeds. The company intends to use any proceeds for working capital and general corporate purposes. ZyVersa will not receive proceeds from the actual resale of shares by the selling stockholders.The prospectus notes that ZyVersa's independent auditors have expressed substantial doubt about the company's ability to continue as a going concern, citing the need for additional funding to execute its business plans. ZyVersa is a clinical-stage biopharmaceutical company developing treatments for renal and inflammatory diseases.